Skip to main content
Atrás
Watch Compare

Polaryx Therapeutics, Inc.

Calidad de datos: 83%
PLYX
NASDAQ Manufacturing Chemicals
$6.17
▲ $0.49 (8.63%)
Cap. Mercado: 265.27 M
Precio
$5.84
Cap. Mercado
265.27 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -3.94 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-196.82%
Below sector avg (-54.47%)
ROIC-135.35%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio8.55
Interest CoverageN/A

Valoración

PE (TTM)
-29.52
Below sector avg (-1.49)
P/B Ratio58.11
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1385 pares)
Métrica Acción Mediana del Sector
P/E -29.5 -1.5
P/B 58.1 1.6
ROE % -196.8 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3

Precio Objetivo de Analistas

1 analista
Strong Buy
Actual
$6.17
+62.1%
Objetivo
$10.00
$10.00
$10.00
$10.00
Pronóstico
EPS Futuro -$0.28
Ingresos Est. 0.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.28
-$0.28 – -$0.28
 0.0 1
FY2026 -$0.12
-$0.12 – -$0.12
 0.0 1

Sorpresas de Ganancias

Último 1 trimestre
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.02 -$0.16 -700.0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -8.99 M
ROE -196.82% ROA -173.79%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3.94 M
ROIC -135.35% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8.55
Interest Coverage N/A Asset Turnover N/A
Working Capital 4.57 M Tangible Book Value 4.57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -29.52 Forward P/E N/A
P/B Ratio 58.11 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1.49%
Market Cap 265.27 M Enterprise Value 260.12 M
Per Share
EPS (Diluted TTM) -0.20 Revenue / Share N/A
FCF / Share -0.09 OCF / Share -0.09
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 43.90%
SBC-Adj. FCF -8.67 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue —
Net Income -8.99 M
EPS (Diluted) -0.20
Gross Profit —
Operating Income -7.82 M
EBITDA —
R&D Expenses 6.27 M
SG&A Expenses —
D&A —
Interest Expense —
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 5.17 M
Total Liabilities 605,000.0
Shareholders' Equity 4.57 M
Total Debt —
Cash & Equivalents 5.14 M
Current Assets 5.17 M
Current Liabilities 605,000.0